Today: 8 June 2026
Browse Category

HKG:029 3 December 2025 - 13 April 2026

Asia Flight Delays and Cancellations Latest: Tokyo, Singapore, Dubai Show Low Disruption as Gulf Route Cuts Persist

Asia Flight Delays and Cancellations Latest: Tokyo, Singapore, Dubai Show Low Disruption as Gulf Route Cuts Persist

Major Asian airports showed low delays Monday, with no regionwide shutdown, according to Cirium FlightStats. Emirates and Dubai Airports reported some cancellations and delays after a partial UAE airspace closure. Singapore Airlines and Cathay Pacific have suspended Dubai flights into June. Jet fuel shortages and longer routes are driving up costs, with India facing added pressure from Dubai’s flight restrictions.
13 April 2026
···
Air China cashes out $170 million Cathay Pacific stake as a Qatar buyback reshapes the shareholder map

Air China cashes out $170 million Cathay Pacific stake as a Qatar buyback reshapes the shareholder map

Air China is selling 108.1 million shares in Cathay Pacific for HK$1.32 billion ($170 million), cutting its stake to just under 30% after a planned buyback. Swire Pacific’s holding will rise to about 47.65%. The sale price is HK$12.22 per share, with completion expected by Jan. 8. Filings show the deal depends on takeover-rule waivers and regulatory approvals.
8 January 2026
·
Cathay Pacific’s Aria Suite Business Class Is Coming to San Francisco in 2026: Dates, Routes, and What Travellers Need to Know

Cathay Pacific’s Aria Suite Business Class Is Coming to San Francisco in 2026: Dates, Routes, and What Travellers Need to Know

Cathay Pacific will launch its Aria Suite business class on the Hong Kong–San Francisco route starting January 3, 2026, marking its first scheduled deployment to the U.S. The Aria-equipped Boeing 777-300ER will operate flights CX872/873 three times weekly. The service offers a full suite door and private seating. Passengers are advised to check aircraft assignments close to departure.
3 December 2025
·

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop